Clinical trials
Phase 3 Hypersensitivity trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
100 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2003 | 2 |
| 2004 | 3 |
| 2005 | 3 |
| 2006 | 7 |
| 2007 | 10 |
| 2008 | 8 |
| 2009 | 2 |
| 2010 | 5 |
| 2011 | 4 |
| 2012 | 2 |
| 2013 | 6 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 6 |
| 2018 | 8 |
| 2020 | 3 |
| 2021 | 7 |
| 2022 | 4 |
| 2024 | 6 |
| 2025 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 79 |
| Recruiting | 6 |
| Withdrawn | 6 |
| Terminated | 4 |
| Unknown status | 4 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| ALK-Abelló A/S | 12 |
| Aimmune Therapeutics, Inc. | 6 |
| Allergopharma GmbH & Co. KG | 6 |
| Inmunotek S.L. | 5 |
| Stallergenes Greer | 5 |
| AstraZeneca | 4 |
| Colgate Palmolive | 4 |
| Alcon Research | 3 |
| Ellodi Pharmaceuticals, LP | 3 |
| Allergy Therapeutics | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hypersensitivity | 100 |
| Rhinitis, Allergic | 14 |
| Hypersensitivity, Immediate | 13 |
| Immune System Diseases | 13 |
| Asthma | 12 |
| Rhinitis, Allergic, Seasonal | 11 |
| Eczema | 10 |
| Dermatitis, Atopic | 8 |
| Peanut Hypersensitivity | 8 |
| Rhinitis | 7 |
Trials
Showing 1 to 25 of 100. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.